Ozempic, Wegovy and research materials: different purposes.

What the medicine names mean.

Ozempic and Wegovy are prescription medicine brands containing semaglutide. Their product-specific prescribing information defines their approved uses and formulation. Sharing a compound name does not make an independently sourced research material the same finished product.

Sources: FDA: approved semaglutide products and compounded-product dosing concerns

A research label is not a treatment recommendation.

A material supplied for laboratory research should not be treated as an alternative to a medicine prescribed for a person. Similar compound names do not establish equivalence of a research material and a finished medicine.

FDA cautions that unapproved versions of GLP-1 products do not undergo its review of safety, effectiveness and quality before marketing. Its guidance advises patients to obtain a prescription from a doctor and fill it through a state-licensed pharmacy.

Sources: FDA: concerns with unapproved GLP-1 drugs

Keep the purpose of the information clear.

A scientific article can explain an experiment or summarize published evidence. It does not establish that an independently sourced research vial has the same composition, quality, formulation or approved use as a medicine described in that article.

For Lotreva, this distinction guides the content as well as the catalog: research explanations should not include instructions for personal dosing, injection, treatment substitution or claims of a customer's medical results.

For readers looking for care.

Questions about prescribed medicines, access or treatment alternatives belong with a qualified healthcare professional. This research-materials preview does not offer medical consultations or prescription dispensing.

Use the FDA source below to understand its current concerns. Regulatory information can change; this page needs a qualified review before release as final educational content.